

In conjunction with the Chicago Medical Society,  
The Chicago Urological Society Presents

# Renal Cancer



2/07/2018  
University Club of Chicago

**Keynote Address:** Michael Blute, MD  
*Massachusetts General Hospital*  
**Program Chair:** Kent Perry, MD

This live activity is designated for a maximum  
of 4.75 AMA PRA Category 1 Credit(s)™

Target Audience: Urologists

## EDUCATIONAL NEEDS

There has been considerable controversy over prostate cancer screening due to concerns about the morbidity that may result from the overtreatment of disease thought to be indolent. Fortunately there have been new data and tools for clinicians that may aid in selecting patients for screening and expectant management.

---

## DESIRED LEARNING OUTCOMES

At the conclusion of this meeting, the attendee should be able to:

1. Describe the genetic aspects to the pathologic characterization of RCC.
2. Understand the evolving management of small renal masses.
3. Discuss the various treatment modalities applicable to RCC and the specific situations in which ablative techniques be considered and situations in which extirpative therapy would be preferred.
4. Describe recent advances in adjuvant RCC treatment and in which patient populations this therapy would be considered.
5. Describe technical considerations and thought process behind the decision to perform partial vs radical nephrectomy in addition to describing when biopsy might also be utilized.
6. Understand what patient characteristics are important when considering cytoreductive nephrectomy.

---

## CME INFORMATION

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Chicago Medical Society and the Chicago Urological Society. The Chicago Medical Society is accredited by the ACCME to provide continuing medical education for physicians.

The Chicago Medical Society designates this live activity for a maximum of **4.75 AMA PRA Category 1 Credit(s)**<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## FACULTY LIST

### Michael Abern, MD, BS

Director of Urologic Oncology, Department of Urology  
The University of Illinois College of Medicine  
Chicago, Illinois

*Dr. Abern has disclosed that he does not have any relevant financial relationships with commercial interests.*

### Kent Sato, MD

Associate Professor of Radiology  
Northwestern Feinberg School of Medicine  
Chicago, Illinois

*Dr. Sato has disclosed that he does not have any relevant financial relationships with commercial interests.*

### Gopal Gupta, MD, FACS

Urologic Oncologist, Department of Urology  
Loyola University, Loyola Medicine  
Chicago, Illinois

*Dr. Gupta has disclosed that he does not have any relevant financial relationships with commercial interests.*

### Robert Nadler, MD

Professor, Department of Urology  
Northwestern Feinberg School of Medicine  
Chicago, Illinois

*Dr. Nadler has disclosed that he does not have any relevant financial relationships with commercial interests.*

### Brian Helfand, MD, PhD

Clinical Associate Professor, Department of Urology  
NorthShore University Health System  
Evanston, Illinois

*Dr. Helfand has disclosed that he does not have any relevant financial relationships with commercial interests.*

### Shilajit D Kundu, MD

Chief of Urologic Oncology, Department of Urology  
Northwestern, Feinberg School of Medicine  
Chicago, Illinois

*Dr. Kundu has disclosed that he holds a consultant relationship with Olympus Corporation of the Americas.*

### Arieh Shalhav, MD

Urologist, Department of Urology  
University of Chicago, School of Medicine  
Chicago, Illinois

*Dr. Shalhav has disclosed that he does not have any relevant financial relationships with commercial interests.*

### Ricardo Soares, MD, FEBU

Endourology Fellow, Department of Urology  
Northwestern University, Feinberg School of Medicine  
Chicago, Illinois

*Dr. Soares has disclosed that he does not have any relevant financial relationships with commercial interests.*

### Marcus Quek, MD, FACS

Professor and Medical Director, Department of Urology  
Loyola University, Loyola Medicine  
Chicago, Illinois

*Dr. Quek has disclosed that he does not have any relevant financial relationships with commercial interests.*

### Michael Blute, MD

Chief of Urology  
Massachusetts General Hospital  
Worcester, Massachusetts

*Dr. Blute has disclosed that he does not have any relevant financial relationships with commercial interests.*

## PROGRAM INFORMATION

**Wednesday, February 7, 2018**

**Program Chair: Kent Perry, MD**

|                 |                                                                                                                           |
|-----------------|---------------------------------------------------------------------------------------------------------------------------|
| 1:00 - 1:25 PM  | Adjuvant Therapy for High Risk RRC: Who benefits?<br>Michael Abern, MD, BS                                                |
| 1:25 - 1:50 PM  | The Management Strategies of Bilateral Renal Masses.<br>Kent Sato, MD                                                     |
| 1:50 - 2:15 PM  | Genetic Characteristics of RRC and Pathological Classification.<br>Gopal Gupta, MD, FACS                                  |
| 2:15 - 2:40 PM  | Ablative Therapies: Back to the Future?<br>Robert Nadler, MD                                                              |
| 2: 40 - 3:05 PM | To Biopsy or Not to Biopsy?<br>Brian Helfand, MD                                                                          |
| 3: 05 - 3:20 PM | Break**                                                                                                                   |
| 3:20 - 3:45 PM  | Cytoreductive Nephrectomy Beyond the IFN Era.<br>Shilajit Kundu, MD                                                       |
| 3:45 - 4:10 PM  | Robotic Partial Nephrectomy: Technical Update.<br>Arieh Shalhav, MD                                                       |
| 4:10 - 4:35 PM  | Partial vs. Radical Nephrectomy: When and Why.<br>Ricardo Soares, MD, FEBU                                                |
| 4:35 - 5:00 PM  | The Management of Small Renal Masses: Neither All Masses<br>nor Patients are Created Equal.<br>Marcus Quek, MD, FACS      |
| 5:00 - 6:00 PM  | Keynote Address: The Role of Surgery in Managing the Primary<br>Metastatic Disease in Kidney Cancer.<br>Michael Blute, MD |
| 6:00 - 7:00 PM  | Cocktails and hors d'oeuvres with Exhibitors*                                                                             |

\* No CME credits awarded

## UNIVERSITY CLUB OF CHICAGO

- ◆ Please note that the Club has a dress code of business casual to business attire.
- ◆ Restrooms are located on the first floor of the Club.
- ◆ Kindly refrain from using your cellular phones in common areas and stairways.

## CLAIMING CME CREDITS

To claim your CME credits, please make sure you check in and sign in upon arrival, and complete both the pre and post surveys provided during the meeting. Your CME certificate will be mailed to you within three (3) months of the meeting date.

## CME PLANNING COMMITTEE

**The following planning members of the Chicago Medical Society's CME Subcommittee on Joint Providership have disclosed that they have no relevant financial relationships with commercial interests:**

Michael Hanak, MD, FAA  
Eric A. Eason, MD  
Arjang Khorasani, MD  
Vemuri S. Murthy, MD

**The following planning members of the Chicago Urological Society have disclosed that they have no relevant financial relationships with any commercial interests:**

Kent Perry, MD, Course Director  
Claire Krieger, Meeting Coordinator

## EXHIBITORS

### PRESIDENT'S TABLE SPONSOR

Abbvie

### PLATINUM SPONSORS

Astellas Oncology  
Astellas Pharmaceuticals  
Ferring Pharmaceuticals  
Myriad Genetics  
Pfizer  
Tolmar Pharmaceuticals

### GOLD SPONSORS

Dendreon

### SILVER SPONSORS

Pacific Edge Diagnostics  
Retrophin  
Allergan

### BRONZE SPONSOR

### SINGLE MEETING SPONSORS

The CUS would like to sincerely thank all of our Exhibitors for their participation in this event. Attendees will have the opportunity to meet with industry representatives in the designated Exhibitor area.



**Next CUS Meeting:**

March 7, 2018